Brixadi
Brixadi is a medication used in the treatment of opioid use disorder. It is a long-acting injectable formulation of buprenorphine, which is a partial opioid agonist. Brixadi is designed to provide sustained release of buprenorphine over a period of time, helping to reduce withdrawal symptoms and cravings in individuals with opioid dependence.
Mechanism of Action[edit | edit source]
Brixadi works by binding to the mu-opioid receptor in the brain, which helps to alleviate withdrawal symptoms and reduce cravings for opioids. As a partial agonist, buprenorphine activates the opioid receptors but to a lesser extent than full agonists like heroin or morphine. This property helps to lower the potential for misuse and dependence.
Administration[edit | edit source]
Brixadi is administered as a subcutaneous injection, typically in the abdominal region. The medication is available in different dosages, allowing healthcare providers to tailor the treatment to the individual needs of the patient. The frequency of administration can vary, but it is generally given on a weekly or monthly basis.
Indications[edit | edit source]
Brixadi is indicated for the treatment of moderate to severe opioid use disorder in patients who have been inducted on a stable dose of transmucosal buprenorphine. It is used as part of a comprehensive treatment plan that includes counseling and psychosocial support.
Side Effects[edit | edit source]
Common side effects of Brixadi include:
Serious side effects may include respiratory depression, especially when used in combination with other central nervous system depressants.
Regulatory Status[edit | edit source]
Brixadi has been approved by various regulatory agencies for the treatment of opioid use disorder. It is classified as a Schedule III controlled substance under the Controlled Substances Act in the United States, indicating a moderate to low potential for physical and psychological dependence.
Related Pages[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
